Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Med Biol Eng Comput ; 41(6): 625-9, 2003 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-14686587

RESUMEN

A new signal processing method for the detection of cyclic variations in atrial fibrillation frequency is presented. The objective was to investigate whether or not respiration, through the autonomic nervous system, modulates the fibrillation frequency in patients with permanent atrial fibrillation. A group of eight patients with permanent atrial fibrillation, atrioventricular block III and a permanent pacemaker were studied during rest, rhythm-controlled respiration, with each breath lasting for 8 s (i.e. a breathing frequency of 0.125 Hz), and rhythm-controlled respiration after full vagal blockade by atropine. Using the new method, a spectral peak could be detected, in two of the patients, at the breathing frequency during rhythm-controlled respiration then disappeared after injection of atropine.


Asunto(s)
Fibrilación Atrial/fisiopatología , Sistema Nervioso Autónomo/fisiopatología , Procesamiento de Señales Asistido por Computador , Anciano , Electrocardiografía , Femenino , Humanos , Masculino , Persona de Mediana Edad , Fenómenos Fisiológicos Respiratorios
2.
IEEE Trans Biomed Eng ; 48(1): 105-11, 2001 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-11235581

RESUMEN

A new method for QRST cancellation is presented for the analysis of atrial fibrillation in the surface electrocardiogram (ECG). The method is based on a spatiotemporal signal model which accounts for dynamic changes in QRS morphology caused, e.g., by variations in the electrical axis of the heart. Using simulated atrial fibrillation signals added to normal ECGs, the results show that the spatiotemporal method performs considerably better than does straightforward average beat subtraction (ABS). In comparison to the ABS method, the average QRST-related error was reduced to 58 percent. The results obtained from ECGs with atrial fibrillation agreed very well with those from simulated fibrillation signals.


Asunto(s)
Fibrilación Atrial/diagnóstico , Procesamiento de Señales Asistido por Computador , Vectorcardiografía , Humanos , Modelos Cardiovasculares , Valores de Referencia
3.
IEEE Trans Biomed Eng ; 48(1): 19-27, 2001 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-11235587

RESUMEN

Time-frequency analysis is considered for characterizing atrial fibrillation in the surface electrocardiogram (ECG). Variations in fundamental frequency of the fibrillatory waves are tracked by using different time-frequency distributions which are appropriate to short- and long-term variations. The cross Wigner-Ville distribution is found to be particularly useful for short-term analysis due to its ability to handle poor signal-to-noise ratios. In patients with chronic atrial fibrillation, substantial short-term variations exist in fibrillation frequency and variations up to 2.5 Hz can be observed within a few seconds. Although time-frequency analysis is performed independently in each lead, short-term variations in fibrillation frequency often exhibit a similar pattern in the leads V1, V2 and V3. Using different techniques for short- and long-term analysis, it is possible to reliably detect subtle long-term changes in fibrillation frequency, e.g., related to an intervention, which otherwise would have been obscured by spontaneous variations in fibrillation frequency.


Asunto(s)
Fibrilación Atrial/diagnóstico , Electrocardiografía , Procesamiento de Señales Asistido por Computador , Enfermedad Crónica , Humanos , Reproducibilidad de los Resultados
4.
Ann Ist Super Sanita ; 37(3): 341-9, 2001.
Artículo en Inglés | MEDLINE | ID: mdl-11889950

RESUMEN

Non-invasive assessment of the fibrillatory frequency of atrial fibrillation (AF) can be performed by frequency domain analysis. The peak frequency in the derived spectrum can be converted to a dominant atrial cycle length (DACL). The DACL can be altered through autonomic modulation or pharmacologic manipulation, but the change in DACL is less marked in those with a short DACL value. In patients with AF, those with a short duration of the arrhythmia have longer DACL values. Finally, patients with paroxysmal AF generally exhibit longer DACL values than patients with permanent AF. Thus non-invasive assessment of the atrial fibrillatory cycle length provides a useful index of atrial refractoriness and has the potential of clinical utility in patient assessment and treatment planning.


Asunto(s)
Fibrilación Atrial/fisiopatología , Antiarrítmicos/uso terapéutico , Fibrilación Atrial/diagnóstico , Fibrilación Atrial/terapia , Sistema Nervioso Autónomo/fisiopatología , Cardioversión Eléctrica , Electrocardiografía , Electrofisiología , Humanos
5.
Biochem Pharmacol ; 60(12): 1807-13, 2000 Dec 15.
Artículo en Inglés | MEDLINE | ID: mdl-11108795

RESUMEN

In the present study, the effects of the combination of tamoxifen ((Z)-2[p-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylamine citrate) and three cannabinoids (Delta(9)-tetrahydrocannabinol [Delta(9)-THC], cannabidiol, and anandamide [AEA]) upon the viability of C6 rat glioma cells was assessed at different incubation times and using different culturing concentrations of foetal bovine serum (FBS). Consistent with previous data for human glioblastoma cells, the tamoxifen sensitivity of the cells was increased as the FBS content of the culture medium was reduced from 10 to 0.4 and 0%. The cells expressed protein kinase C alpha and calmodulin (the concentration of which did not change significantly as the FBS concentration was reduced), but did not express estrogen receptors. Delta(9)-THC and cannabidiol, but not AEA, produced a modest reduction in cell viability after 6 days of incubation in serum-free medium, whereas no effects were seen in 10% FBS-containing medium. There was no observed synergy between the effects of tamoxifen and the cannabinoids upon cell viability.


Asunto(s)
Antineoplásicos Fitogénicos/farmacología , Sangre , Cannabinoides/farmacología , Tamoxifeno/farmacología , Animales , Calmodulina/biosíntesis , Supervivencia Celular/efectos de los fármacos , Interacciones Farmacológicas , Glioma/patología , Isoenzimas/biosíntesis , Proteína Quinasa C/biosíntesis , Proteína Quinasa C-alfa , Ratas , Receptores de Estrógenos/biosíntesis , Células Tumorales Cultivadas
6.
Europace ; 1(4): 234-41, 1999 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-11220560

RESUMEN

AIMS: Electrical remodelling with shortening of the atrial refractory period and increased fibrillatory rate occurs after onset of atrial fibrillation and can be attenuated by pre-treatment with intravenous verapamil. The aim of the present study was to investigate whether already established fibrillatory-induced shortening of atrial fibrillatory cycle length could be reversed with oral verapamil. METHODS AND RESULTS: Thirteen patients (nine men; mean age 67 years) with chronic atrial fibrillation (CAF) were studied. The dominant atrial cycle length (DACL) was estimated non-invasively using the frequency analysis of fibrillatory ECG (FAF-ECG) method. Measurements were repeated following treatment with slow release oral verapamil. DACL increased from 147 +/- 13 ms to 156 +/- 21 ms after 1 day (P=0.02), to 164 +/- 18 ms after 5 days (P=0.005) and finally to 160 +/- 16 ms after 6 weeks (P=0.008). CONCLUSION: Long-term oral treatment with verapamil increases the DACL significantly in patients with CAF. The prolongation is evident after 1 day and is further developed during the first 5 days of treatment. Since DACL is believed to be an index of refractoriness, the findings of the present study suggest that this treatment increases the atrial refractory period in patients with CAF.


Asunto(s)
Antiarrítmicos/farmacología , Fibrilación Atrial/fisiopatología , Sistema de Conducción Cardíaco/efectos de los fármacos , Verapamilo/farmacología , Anciano , Antiarrítmicos/uso terapéutico , Fibrilación Atrial/tratamiento farmacológico , Presión Sanguínea/efectos de los fármacos , Enfermedad Crónica , Femenino , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Masculino , Persona de Mediana Edad , Verapamilo/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...